Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration

Retina

Volumn 35, Issue 10, 2015, Pages 1957-1963

  Toth, Levente A ^a,b   Stevenson, Michael ^b   Chakravarthy, Usha ^a,b  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Age related macular degeneration; Inhibition of vascular endothelial growth factor; Predictors of visual outcome

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PATIENT CARE; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA DISEASE; RETINAL ANGIOMATOUS PROLIFERATION; RETROSPECTIVE STUDY; VERY ELDERLY; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VISION, LOW; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION, LOW; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84942426457     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000583     Document Type: Article

References (21)

1. Bressler NM, Chang TS, Suner IJ, et al. Vision-related function after ranibizumab treatment by better-or worse-seeing eye. Clinical trial results from MARINA and ANCHOR. Ophthalmology 2010;117:747-756.e4.
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
3. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857.e4.
4. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-252.
5. Kaiser PK, Blodi BA, Shapiro H, et al; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114: 1868-1875.e4.
6. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-1267.
7. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
8. Martin DF, Maguire MG, Ying G, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
9. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119: 1388-1398. Epub 2012 May 1.
10. Jaffe GJ, Martin DF, Toth CA, et al; Comparison of Agerelated Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2013;120:1860-1870. Epub 2013 May 1.
11. Ying GS, Huang J, Maguire MG, et al; Comparison of Agerelated Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-129. Epub 2012 Oct 6.
12. Daniel E, Toth CA, Grunwald JE, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:656-666. Epub 2013 Dec 4.
13. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1220-1231.
14. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109:1242-1257.
15. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol 1994; 112:500-509.
16. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-126.
17. Schmidt-Erfurth U, Kaiser PK, Korobelnik J, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
18. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab Curr Med Res Opin 2011;27:1465-1475. COCHRANE RW.
19. NICE Technology appraisals T. Pegaptanib and ranibizumab for the treatment of age-related macular degeneration. NICE Guidelines 2008.
20. de Amorim Garcia Filho CA, Penha FM, Gregori G, Rosenfeld PJ. Increasing volume of a retinal pigmented epithelial detachment as a predictor of submacular hemorrhage during anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina 2013;44:204-207.
21. Stevenson MR, Hart PM, Montgomery A, et al. Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. Br J Ophthalmol 2004;88:1125-1130.